In a report released yesterday, Julian Harrison from BTIG maintained a Hold rating on Morphic Holding (MORF – Research Report). The company’s shares closed last Friday at $22.57.
According to TipRanks, Harrison is an analyst with an average return of -2.4% and a 32.04% success rate. Harrison covers the Healthcare sector, focusing on stocks such as MoonLake Immunotherapeutics, Aclaris Therapeutics, and Liquidia Technologies.
Currently, the analyst consensus on Morphic Holding is a Moderate Buy with an average price target of $56.75.
See the top stocks recommended by analysts >>
The company has a one-year high of $63.08 and a one-year low of $19.35. Currently, Morphic Holding has an average volume of 1.08M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Morphic Holding (MORF) Company Description:
Morphic Holding, Inc. operates as a biopharmaceutical company, which engages in the research and development of oral small-molecule integrin therapeutics. It operates a Morphic integrin technology platform, MInT platform, to create a broad pipeline of programs across a variety of therapeutic areas. The company was founded by Timothy A. Springer in August 2014 and is headquartered in Waltham, MA.
Read More on MORF:
- Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2023
- Morphic expects cash to fund operations through second half of 2027
- Morphic reports Q3 EPS (73c), consensus (95c)
- Morphic Therapeutic to Host Webcast to Present EMERALD-1 Full Data Set
- Biotech Alert: Searches spiking for these stocks today
